financetom
Business
financetom
/
Business
/
Expedia Q2 Adjusted Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Expedia Q2 Adjusted Earnings, Revenue Rise
Aug 8, 2024 1:51 PM

04:15 PM EDT, 08/08/2024 (MT Newswires) -- Expedia ( EXPE ) reported Q2 adjusted earnings late Thursday of $3.51 per share, up from $2.89 a year earlier.

Analysts polled by Capital IQ expected $3.16.

Revenue for the quarter ended June 30 was $3.56 billion, up from $3.36 billion a year earlier.

Analysts surveyed by Capital IQ expected $3.53 billion.

Shares were down 3% in after-hours trading.

Price: 114.16, Change: -3.81, Percent Change: -3.23

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
South Africa's RCL Foods reports 38.8% rise in half-year earnings
South Africa's RCL Foods reports 38.8% rise in half-year earnings
Mar 2, 2025
JOHANNESBURG (Reuters) - South African food producer RCL Foods reported on Monday a 38.8% rise in half-year earnings, largely due to gains in its groceries and baking businesses. RCL Foods, whose brands include Selati sugar, Yum Yum peanut butter and Sunbake bread, said headline earnings per share from continuing operations rose to 109.4 South African cents in the six months...
Ex-Barclays CEO Staley appeals UK ban over Epstein statements
Ex-Barclays CEO Staley appeals UK ban over Epstein statements
Mar 2, 2025
LONDON, March 3 (Reuters) - Former Barclays boss Jes Staley will on Monday mount a high-profile appeal against his proposed ban from Britain's finance industry, which will once again highlight his relationship with disgraced financier Jeffrey Epstein. Staley - also a former executive at JPMorgan ( JPM ), where Epstein was once a major private banking client - has been...
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's Sun Pharma aims to launch its obesity drug in five years, managing director says
Mar 2, 2025
By Rishika Sadam MUMBAI, March 1 (Reuters) - India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said on Friday. The company is among many Indian drugmakers looking to grab a slice of the growing weight-loss drug market, which...
Ex-Barclays CEO Staley appeals UK ban over Epstein statements
Ex-Barclays CEO Staley appeals UK ban over Epstein statements
Mar 2, 2025
LONDON (Reuters) - Former Barclays boss Jes Staley will on Monday mount a high-profile appeal against his proposed ban from Britain's finance industry, which will once again highlight his relationship with disgraced financier Jeffrey Epstein. Staley - also a former executive at JPMorgan, where Epstein was once a major private banking client - has been battling to clear his name...
Copyright 2023-2026 - www.financetom.com All Rights Reserved